Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers

Although fatigue is a common symptom in multiple sclerosis (MS), its pathomechanisms are incompletely understood. Glatiramer acetate (GA), an immunomodulatory agent approved for treatment of relapsing-remitting MS (RRMS), possesses unique mechanisms of action and has been shown to exhibit beneficial...

Descripción completa

Detalles Bibliográficos
Autores principales: Neuhaus, Oliver, Köhler, Wolfgang, Then Bergh, Florian, Kristoferitsch, Wolfgang, Faiss, Jürgen, Rosenkranz, Thorsten, Reske, Dirk, Patejdl, Robert, Hartung, Hans-Peter, Zettl, Uwe K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002075/
https://www.ncbi.nlm.nih.gov/pubmed/33800033
http://dx.doi.org/10.3390/biom11030393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8002075/
https://www.ncbi.nlm.nih.gov/pubmed/33800033
http://dx.doi.org/10.3390/biom11030393

Ejemplares similares